Award
Eunice Kennedy Shriver National Institute of Child Health and Human Development 5R44HD112276-03
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates
Recipient
AYUVIS RESEARCH, INC.
Award Amount
$359,812.00
Ceiling
$359,812.00
Awarded
May 25, 2026
Identifier
5R44HD112276-03
This award funds clinical trials to evaluate the safety, pharmacokinetics, and efficacy of AVR-48, a novel small molecule aimed at preventing bronchopulmonary dysplasia in preterm infants, with the goal of developing a prophylactic treatment.
Description
AyuVis Research is developing a novel class of immunomodulating small molecules derived from chitin to prevent and treat bronchopulmonary dysplasia (BPD) in preterm infants. The project involves clinical trials to assess safety, pharmacokinetics, and efficacy of the lead compound AVR-48 in both healthy adult volunteers and preterm infants at risk of BPD.